Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

AstraZeneca ramps up investment in Dunkerque

04 Nov 2013 | Investment, Health Nutrition

AstraZeneca will invest €26 million in a new production line for the Symbicourt asthma inhaler at its Dunkerque plant. Existing lines will also be upgraded.

AstraZeneca -  pharmaceutical laboratory - Symbicort - health - Lille Region

            Present in Dunkerque for over 20 years, pharmaceutical giant AstraZeneca has invested some €500 million in its local plant to date—outlays that reflect the facility’s strategic importance as the world’s sole producer of Symbicort inhalers. With demand for the asthma remedy on the rise, the plant needed new capacity. “The aerosol technology we use for this inhaler is fairly unique within our group, and is concentrated at Dunkerque,” says Plant Manager Dominique Bretaudeau.

            The plant, which exports 95% of its total output to the United States, has a long tradition of meeting challenges and adapting to changing patient needs. In addition to special projects, it invests around €2.5 million a year to upgrade and maintain equipment, enhance patient safety and improve packaging.

            AstraZeneca is one of the world’s top pharmaceutical companies and ranks fifth in the field in France. Its medicines cover six main therapeutic areas: cardiovascular & metabolic, infection, gastrointestinal, oncology, neurosciences and respiratory ailments. Sales total around $28 billion, with over $4 million invested in R&D each year.

 

Source: AstraZeneca / Press

Back to news

News

Liberty House moves to acquire Aluminium Dunkerque

GFG Alliance—the holding company for Liberty House—is set to acquire the Aluminium Dunkerque plant in Hauts-de-France for $500 million, and the British group is already planning more investments.

Emile Awards shine spotlight on Hauts-de-France

On December 8, Lille hosted the first Emile Awards, honoring Europe’s finest animated films—and underscoring the region’s role as a rising star in the industry.

All news